NKTR102 Demonstrates Synergistic AntiTumor Activity in Combination with Pegylated Liposomal Doxorubicin in PlatinumResistant Ovarian Cancer

SAN FRANCISCO Nov. 15 2011 PRNewswire Nektar Therapeutics NASDAQNKTR today presented positive preclinical data for NKTR102 a nextgeneration topoisomerase I inhibitor at the 2011 AACRNCIEORTC International Conference on Molecular Targets and Cancer being h...